Products & Pipeline

全图-管线图英文20190830.jpg

* In-house programs

Note: The Group is also developing the tablet formulation of Ritonavir and has completed bioequivalence (BE) studies of the tablets on healthy volunteers. ANDA of Ritonavir was accepted by NMPA on August 22, 2019. Ritonavir is used as a pharmacokinetic booster of Ganovo® (Danoprevir).